Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

Inclusion Criteria: * Patients with chronic hepatitis B aged 18 years or older * Subjects who have evidence to demonstrate a history of chronic hepatitis B for at least six months from the time of screening visit * Subjects who have HBsAg positive test at screening visit * Subjects who did not receive the hepatitis B treatment, including interferon or pegylated interferon, within 24 weeks of starting the screening test * Subjects with an ALT of 80 units or more and 10 times lower than the normal upper limit at the time of screening Exclusion Criteria: * Subjects infected with hepatitis C, hepatitis D or human immunodeficiency virus * Subjects with creatinine clearance of less than 50 ml/min at the screening visit * At the time of screening visit, alpha-fetoprotein level was higher than 50 ng/ml and related imaging test showed hepatocellular carcinoma * Subjects with decompensated liver disease who meet the following criteria: 1. Total bilirubin levels greater than 2.5 mg/dl 2. Prothrombin time is at least 3 seconds longer than normal upper limit 3. Serum albumin value less than 30 g/l 4. Subjects with a history of ascites, jaundice, bleeding from varicose veins, hepatic encephalopathy, or other signs of liver failure.